Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Glaucoma and Ocular Hypertension
Phase PHASE3
Enrollment 790
Locations 29 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Low Energy SLT — SLT performed at low energy
  • Procedure: Standard Energy SLT — SLT performed at standard energy

Primary Outcomes

  • 12-month survival (12 months)
  • 48-month survival (48 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2021-09-07
Completion: 2027-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 790 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pittsburgh
Collaborators: National Eye Institute (NEI), West Virginia University
Principal Investigators:
  • Tony Realini, MD, MPH (STUDY_CHAIR) - West Virginia University
  • Goundappa K Balasubramani, PhD (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
  • Stephen Wisniewski, PhD (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Tony Realini, MD, MPH
3045986926
hypotonywvu@gmail.com
Ashwini Ravichandran
949-951-2020
aravichandran@harvardeye.com
Harvard Eye Associates
Ye Elaine Wang, MD
Harvard Eye Associates
Interventions
  • Procedure: Low Energy SLT — SLT performed at low energy
  • Procedure: Standard Energy SLT — SLT performed at standard energy
Study Locations (29 sites)
Harvard Eye Associates, Laguna Hills, California 92653 United States
Doheny Eye Center UCLA, Pasadena, California 91105 United States
University of California, Davis, Sacramento, California 95817 United States
University of California, San Francisco, San Francisco, California 94158 United States
Mile High Eye Institute, Sheridan, Colorado 80110 United States
Clear Vue Laser Eye Center, Lakeworth, Florida 33467 United States
Northwestern Medical Group, Chicago, Illinois 60615 United States
Chicago Arbor Eye Institute, Orland Park, Illinois 60467 United States
Illinois Eye Center, Peoria, Illinois 61615 United States
Wilmer Eye Institute Johns Hopkins, Baltimore, Maryland 21287 United States
Eligibility Criteria
Inclusion Criteria: 1. Age 18 or older and in good health 2. Each eye with one of the following qualifying diagnoses (diagnoses may differ between eyes): 1. High-risk ocular hypertension (OHT): IOP \> 21 mmHg without glaucomatous optic neuropathy (excavation, diffuse or focal thinning or notching of the neuroretinal rim, visible nerve fiber layer defects, or asymmetry of the vertical cup-to-disc ratio of \>0.2 between eyes) 2. Mild primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation better than -6.0 dB with no points in the central 5° \<15 dB (see figure on next page) 3. Moderate primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dB and no central 5° points \<15 dB or mean deviation -12.0 dB or better with 1 central 5° points \<15 dB (see figure on next page). 3. Each eye with BCVA 20/200 (UK 6/60) or better Exclusion Criteria: 1. Use of topical IOP-lowering medications for more than 6 cumulative months at any time in the past 5 years (this is a modification implemented during active enrollment) 2. Any history of IOP-lowering laser (prophylactic iridotomy not included) or surgical procedure 3. Advanced POAG in either eye (worse than moderate POAG as defined above) 4. Glaucoma other than POAG (including pigmentary and pseudoexfoliation glaucoma) in either eye 5. Mean IOP \> 35 mmHg at either the screening or baseline visit in either eye 6. Narrow or closed angle (Shaffer Grade 0, 1, or 2) in either eye 7. Contraindications to SLT or any other study intervention 8. Any corneal pathology that would preclude accurate assessment of IOP by Goldmann tonometry in either eye 9. Any intraocular surgical procedure within the past 6 months in either eye 10. Inability to attend all scheduled study visits 11. Pregnant or planning to become pregnant in the next 4 years
Conditions Obesity, Diabetes Type 2
Phase PHASE1
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests (FSIGT) both before and after semaglutide for six weeks. The proposal proposes two specific aims: 1. Specific Aim #1. To identify genetic variants associated with effects of a GLP1R agonist to enhance glucose-stimulated first phase insulin secretion in the two FSIGTs (before and after administration of drug). 2. Specific Aim #2. To identify genetic variants associated with the effect of a GLP1R agonist to accelerate the rate of glucose disappearance as assessed in the two FSIGTs (before and after administration of drug). Genotyping will be conducted using a high-density array with comprehensive coverage of DNA sequence variants. In addition, the analysis will leverage a global imputation panel generated from 1,025 Amish individuals.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Drug: Semaglutide Pen Injector [Ozempic] — Participants will receive subcutaneously injected semaglutide (0.25 mg/wk) for 4 weeks followed by semaglutide (0.5 mg/wk) for an additional two weeks.

Primary Outcomes

  • First phase insulin secretion (Measured both at baseline and after completing 6 weeks of semaglutide therapy)
  • Second phase insulin secretion (Measured both at baseline and after completing 6 weeks of semaglutide therapy)
  • Rate of glucose disappearance (Measured both at baseline and after completing 6 weeks of semaglutide therapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2022-04-11
Completion: 2028-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Maryland, Baltimore
Principal Investigators:
  • Amber L Beitelshees, PharmD (PRINCIPAL_INVESTIGATOR) - University of Maryland, Baltimore
Contact Information
Study Contact:
Amber L Beitelshees, PharmD
(410)706-0118
abeitels@som.umaryland.edu
Simeon I Taylor, MD, PhD
(410)706-6439
staylor2@som.umaryland.edu
Susan Shaub, RN
(717)392-4948
sshaub@som.umaryland.edu
Amish Research Clinic
Interventions
  • Drug: Semaglutide Pen Injector [Ozempic] — Participants will receive subcutaneously injected semaglutide (0.25 mg/wk) for 4 weeks followed by semaglutide (0.5 mg/wk) for an additional two weeks.
Study Locations (1 sites)
Amish Research Clinic, Lancaster, Pennsylvania 17602 United States
Eligibility Criteria
Inclusion Criteria: * BMI greater than or equal to 27 kg/m2 * Of Amish Descent Exclusion Criteria: * Woman of childbearing age who is sexually active * History of diabetes (HbA1c \> 6.5% or random glucose \>200 mg/dL) * Known allergy to semaglutide * Medical issues, which in the judgment of the research physician or PIs might increase the risk associated with participation in the study * eGFR \< 60 mL/min/1.73 sq. m. * Hematocrit \< 35% * TSH \< 0.4 o4 \> 5.5 * AST or ALT in excess of 2X the upper limit of normal * Unable to discontinue a drug, vitamin, or nutritional supplement, which in the judgment of the research physician or PIs might alter the response to semaglutide * Personal or family history of medullary carcinoma of the thyroid or multiple endocrine neoplasia, type 2
Conditions Cognitive Decline, Blood Pressure, Hyper...
Phase NA
Enrollment 4000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The PCOT study is a multi-site randomized trial of patients 70 years or older with high BP. The main goal of the study Preventing Cognitive Decline by Reducing BP Target Trial (PCOT) is to conduct a large pragmatic clinical trial (PCT) to test the hypothesis that patients who receive care with a combination of clinical decision support (CDS) and team-based care delivered in primary care practices will have better blood pressure control and a lower incidence of mild cognitive impairment and dementia than patients receiving usual medical care. Patients will be recruited from UT Southwestern Medical Center and Parkland Health \& Hospital System.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Other: Clinical Support Decision Tool — Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the Clinical Decision Support (CDS) tool to assist their physicians with their blood pressure management. Home BP data will be averaged each month via Omron Connect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health. We have designed CDS to present treatment choices of antihypertensive medication regimen based on medications patients are currently taking. For example, patients who are currently taking an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), our CDS algorithm will recommend addition of a calcium channel blocker as the first tier of recommendation and thiazide diuretics as second tier of recommendation. Laboratory data and home BP in the past month will be presented in a clear and simple manner for the clinicians to activate and use to optimize BP control.

Primary Outcomes

  • Cognitive Decline (4 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-07-11
Completion: 2026-08-31
Eligibility
Age: 70 Years and older
Sex: ALL
Volunteers: false
Enrollment: 4000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Texas Southwestern Medical Center
Collaborators: National Institute on Aging (NIA), Duke University, Parkland Health and Hospital System
Contact Information
Study Contact:
Venkatraghavan Sundaram, Ph.D.
214-590-3848
venkatraghavan.sundaram@phhs.org
Miguel Vazquez, MD
214-648-3442
miguel.vazquez@utsoutwestern.edu
Miguel Vazquez, MD
214-648-3442
Miguel.Vazquez@UTSouthwestern.edu
UT Southwestern Medical Center
Interventions
  • Other: Clinical Support Decision Tool — Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the Clinical Decision Support (CDS) tool to assist their physicians with their blood pressure management. Home BP data will be averaged each month via Omron Connect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health. We have designed CDS to present treatment choices of antihypertensive medication regimen based on medications patients are currently taking. For example, patients who are currently taking an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), our CDS algorithm will recommend addition of a calcium channel blocker as the first tier of recommendation and thiazide diuretics as second tier of recommendation. Laboratory data and home BP in the past month will be presented in a clear and simple manner for the clinicians to activate and use to optimize BP control.
Study Locations (1 sites)
UT Southwestern Medical Center, Dallas, Texas 75390 United States
Eligibility Criteria
Inclusion Criteria: * High BP defined as at least 1 BP readings of SBP \>= 130 or DBP \>=80 during the 24 months prior to enrollment * Clinic visit with primary care provider within the last 24 months * Ability to write and speak English or Spanish * 70 years of age or older * Ability to understand and willingness to provide informed consent * Owns a smartphone Exclusion Criteria: * Blood pressure consistently \<130/80 mmHg * Presence of dementia, Alzheimer's disease, or significant neurological disease * Major and unstable heart disease (e.g., acute heart failure (systolic or diastolic), acute on chronic heart failure (systolic or diastolic), acute coronary syndrome or cardiac arrest, liver or renal transplantation * Under 70 years of age * Inability to write or speak English or Spanish * Chronic kidney disease stage 5 or ESKD * Chemotherapy * Any conditions judged by the medical providers to contraindicate participation due to risk to patient safety or lack of adherence * Expected life expectancy under a year

Left vs. Right Non-Inferiority Trial

NCT04999553
Recruiting
Conditions Depression, Major Depressive Disorder, M...
Phase NA
Enrollment 480
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to test the hypothesis that low-frequency rTMS (LFR) works as well as the established intermittent thetaburst rTMS (iTBS) treatment for treatment resistant depression (TRD).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Repetitive Transcranial Magnetic Stimulation — rTMS will employ the MagPro X100/R30 stimulator equipped with the cool-B70 as we used a cool-B70 in our past non-inferiority trial. The dose will be a 120% rMT in accordance to our latest trial using iTBS. The target area to stimulate will be the right dorsolateral prefrontal cortex (DLPFC) for LFR and the left DLPFC for iTBS as established in prior clinical trials. The localization of both targets will follow the well-established procedures for either R-DLPFC or L-DLPFC using a heuristic method.
  • Device: Intermittent Theta Burst Stimulation (iTBS) — Intermittent Theta Burst Stimulation (iTBS)
  • Device: Low Frequency Right (LFR) — Low Frequency Right (LFR)

Primary Outcomes

  • Depression severity (30 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-11-08
Completion: 2027-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 480 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of British Columbia
Collaborators: Centre for Addiction and Mental Health
Principal Investigators:
  • Fidel Vila-Rodriguez, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of British Columbia
Contact Information
Study Contact:
Amanda Ding
604-827-1361
ninet.lab@ubc.ca
Amanda Ding
6048221361
ninet.lab@ubc.ca
Non-Invasive Neurostimulation Therapies Centre, University of British Columbia
Fidel Vila-Rodriguez, MD, PhD
Non-Invasive Neurostimulation Therapies Centre, University of British Columbia
Interventions
  • Device: Repetitive Transcranial Magnetic Stimulation — rTMS will employ the MagPro X100/R30 stimulator equipped with the cool-B70 as we used a cool-B70 in our past non-inferiority trial. The dose will be a 120% rMT in accordance to our latest trial using iTBS. The target area to stimulate will be the right dorsolateral prefrontal cortex (DLPFC) for LFR and the left DLPFC for iTBS as established in prior clinical trials. The localization of both targets will follow the well-established procedures for either R-DLPFC or L-DLPFC using a heuristic method.
  • Device: Intermittent Theta Burst Stimulation (iTBS) — Intermittent Theta Burst Stimulation (iTBS)
  • Device: Low Frequency Right (LFR) — Low Frequency Right (LFR)
Study Locations (2 sites)
Non-Invasive Neurostimulation Therapies Centre, University of British Columbia, Vancouver, British Columbia V6T 2A1 Canada
Centre for Addiction and Mental Health, Toronto, Ontario M6J 1H4 Canada
Eligibility Criteria
Inclusion Criteria: 1. are female or male; 2. are outpatients; 3. are voluntary and competent to consent to treatment; 4. have a DSM 5 diagnosis of MDD,55 single or recurrent confirmed by Mini-International Neuropsychiatric Interview (MINI) version 7.0; 5. are 18yo to 65yo; 6. have failed to achieve a clinical response to an adequate dose of an antidepressant based on an Antidepressant Treatment History Form (ATHF) score of \> 3 in the current episode OR have been unable to tolerate at least two separate trials of antidepressants at less than the minimum adequate dose and/or duration (ATHF 1 or 2); 7. have a score ≥ 18 on the Hamilton Depression Rating Scale (HDRS-17 item); 8. have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening; 9. are able to adhere to the treatment schedule; 10. pass the TMS and MRI adult safety screening questionnaires. Exclusion Criteria: 1. have a history of substance use within the last 3 months; 2. have a concomitant major unstable medical illness; 3. have active suicidal intent; 4. are pregnant; 5. have a lifetime (MINI) diagnosis of any psychotic or bipolar disorder; 6. have a MINI anxiety disorder or personality disorder assessed by a study investigator to be primary and causing greater impairment than MDD; 7. have failed a course of ECT in the current episode; 8. have any significant neurological disorder, any history of seizure (except those therapeutically induced by ECT), significant head trauma with loss of consciousness for \> 5 min; 9. have any intracranial implant (e.g., aneurysm clips) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed; 10. are participating in psychotherapy, must have been in stable treatment for at least 3 months prior to study entry, with no anticipated change in the frequency of therapeutic sessions, or focus of therapeutic sessions over the duration of the study; 11. have a clinically significant laboratory abnormality, in the opinion of the one of the principal investigators; 12. have a non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview);

Treatment Interrupts Depression Early

NCT05002309
Recruiting
Conditions Depression
Phase PHASE2
Enrollment 100
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The TIDE project aims to establish personal indicators for initial treatment choice for youth with first episode depression. Specifically, 100 adolescents and young adults (age 12 to 25) with untreated major depressive disorder of recent onset will be randomly allocated in 1:1 ratio to one of two evidence-based regimens for youth depression: (A) Individual cognitive-behavioural therapy; and (B) Optimized pharmacological treatment with an antidepressant. All participants will be offered active treatment for up to 1 year and follow-up for 2 years to establish short- and long-term outcomes, including change in depressive symptoms, maintenance of remission, core role functioning, achievement of educational, occupational and social milestones, and quality of life. Baseline characteristics including duration of untreated depression, pre-existing anxiety, attention-deficit/hyperactivity disorder, substance use, symptoms of reduced interest and activity, sleep, rhythm and melody of speech, brain function, history of childhood adversity, coping style, repetitive thinking, and family history of depression and bipolar disorder will be tested as potential moderators of outcome. Characteristics that differentially predict outcomes in those allocated to initial cognitive-behavioural therapy and those allocated to initial treatment with antidepressants will be combined into a personalized allocation algorithm.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Cognitive-Behavioural Therapy — 20 sessions of individual CBT are offered over 16 weeks, conducted 1-on-1, with a trained and supervised therapist. Participants will learn about the cognitive, behavioural, emotional, and environmental factors which contribute to maintaining their depression. They will apply skills to interrupt unhelpful cognitive and behavioural patterns and engage in guided exploration to improve self-understanding. CBT is a structured and collaborative treatment. Weekly "homework" will be used to maximize opportunities for practice and consolidation of new skills. The individual sessions can be combined with optional family/parent/partner sessions, depending on the situation and preferences of the participant. All sessions will be video-recorded to allow high-quality supervision, fidelity- and quality-assurance. This corresponds to evidence available for CBT for adolescents and young adults that is established as the best practice through rigorous trials.
  • Drug: Antidepressant medication — The choice of antidepressants follows best-established evidence for treating depression in adolescents and young adults. We will offer treatment with fluoxetine, starting at 10mg a day, increasing to 20mg a day after 1 week if tolerated; a protocol established as safe and effective in adolescents and adults in multiple trials. Additional increases to 40 or 60mg will be possible based on positive effects and side-effects and clinical judgement, as recommended in this age group. In cases of intolerance or adverse reaction to fluoxetine, we will switch to sertraline (25-200mg) or escitalopram (5-20mg), two antidepressants licensed by the FDA for major depressive disorder in adolescents. Treatment will be optimized over 16 weeks, a time-frame comparable to the CBT arm. Pharmacotherapy will be managed and prescribed by qualified psychiatrists when starting treatment and reviewed after 1 week, 2 weeks and then in 2-weekly intervals for the remainder of the 16 weeks acute treatment period.

Primary Outcomes

  • Severity of depressive symptoms (1-16 weeks)
  • Severity of depressive symptoms (16-32 weeks)
  • Proportion of time spent depression free (16-104 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-12-02
Completion: 2028-12-31
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nova Scotia Health Authority
Principal Investigators:
  • Rudolf Uher, MD, PhD (PRINCIPAL_INVESTIGATOR) - Nova Scotia Health Authority
Contact Information
Study Contact:
Rudolf Uher, MD, PhD
902-473-7209
uher@dal.ca
Jill Cumby, RN, MN
902-473-1781
jill.cumby@nshealth.ca
Philippe Guévremont, MDCM
514-761-6131
inspirelab.tide@gmail.com
Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l'Île-de-Montréal / Centre de Recherche Douglas (Montreal West Island IUHSSC / Douglas Research Center)
Interventions
  • Behavioral: Cognitive-Behavioural Therapy — 20 sessions of individual CBT are offered over 16 weeks, conducted 1-on-1, with a trained and supervised therapist. Participants will learn about the cognitive, behavioural, emotional, and environmental factors which contribute to maintaining their depression. They will apply skills to interrupt unhelpful cognitive and behavioural patterns and engage in guided exploration to improve self-understanding. CBT is a structured and collaborative treatment. Weekly "homework" will be used to maximize opportunities for practice and consolidation of new skills. The individual sessions can be combined with optional family/parent/partner sessions, depending on the situation and preferences of the participant. All sessions will be video-recorded to allow high-quality supervision, fidelity- and quality-assurance. This corresponds to evidence available for CBT for adolescents and young adults that is established as the best practice through rigorous trials.
  • Drug: Antidepressant medication — The choice of antidepressants follows best-established evidence for treating depression in adolescents and young adults. We will offer treatment with fluoxetine, starting at 10mg a day, increasing to 20mg a day after 1 week if tolerated; a protocol established as safe and effective in adolescents and adults in multiple trials. Additional increases to 40 or 60mg will be possible based on positive effects and side-effects and clinical judgement, as recommended in this age group. In cases of intolerance or adverse reaction to fluoxetine, we will switch to sertraline (25-200mg) or escitalopram (5-20mg), two antidepressants licensed by the FDA for major depressive disorder in adolescents. Treatment will be optimized over 16 weeks, a time-frame comparable to the CBT arm. Pharmacotherapy will be managed and prescribed by qualified psychiatrists when starting treatment and reviewed after 1 week, 2 weeks and then in 2-weekly intervals for the remainder of the 16 weeks acute treatment period.
Study Locations (2 sites)
Nova Scotia Health, Halifax, Nova Scotia B#H 2E2 Canada
Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l'Île-de-Montréal / Centre de Recherche Douglas (Montreal West Island IUHSSC / Douglas Research Center), Montreal, Quebec H4H 1R3 Canada
Eligibility Criteria
Inclusion Criteria: * Age 12-25 years * Diagnosis of major depressive disorder, onset of the major depressive disorder within the last 12 months. Depression considered the most significant problem in need of treatment. * An additional inclusion criterion for entering Stage 1 (active intervention) is a minimum moderate depression severity (CDRS-R≥40; MADRS≥20) that justifies the need for treatment. Individuals who fulfill general inclusion criteria but are below the depression severity threshold for active intervention will still be eligible to participate in follow-up assessments. * Verbal ability sufficient to participate in psychological treatment. Exclusion Criteria: * Personal history of a manic or hypomanic episode, diagnosis of a psychotic disorder, pervasive developmental disorder or autism spectrum disorder, intellectual disability, mental disorders secondary to neurological or other medical condition, active substance use disorder. * Previous trial of any treatment for major depressive disorder lasting 4 weeks or longer, current use of antipsychotic, antidepressant or mood-stabilizer medication. * Recent (past 6 weeks) change in any psychotropic medication (including stimulants, hypnotics, anxiolytics) or receipt of 4 of more sessions of cognitive-behavioural therapy. * Pregnancy or breastfeeding. If participants become pregnant or learn of pregnancies during the study, we will consult with Dr. Tanya Tulipan and jointly make the best decision for the participant with the option to either continue or end study treatment. * No one will be excluded based on sex, gender, race, ethnicity, or living arrangements.
Conditions Multiple Sclerosis, Major Depressive Dis...
Phase NA
Enrollment 146
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research is to examine the effects of two different exercise training regimens for managing depression and improving other health indicators among persons with multiple sclerosis (MS). The project will enroll persons with MS and major depressive disorder (MDD) between 18 and 64 years of age. The investigators will enroll a total of 146 participants. This is a Phase-II trial that compares the efficacy of an exercise training program (POWER-MS) compared with a stretching program (FLEX-MS) for immediate and sustained reductions in the severity of depression among persons with MS who have MDD.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: POWER-MS — The POWER-MS intervention includes both aerobic exercise and resistance exercise: Aerobic Exercise: The goal of the aerobic exercise training is for participants to achieve three moderate-intensity walking sessions of 30+ minutes per session by the end of the 16-week intervention. Resistance Exercise: Participants will complete resistance exercise training that consists of 1-2 sets (10-15 repetitions) of 5-10 exercises targeting the lower body, upper body, and core muscle groups performed three days per week, with the sets, repetitions and number of exercises increasing based on an individualized difficulty level.
  • Behavioral: FLEX-MS — The FLEX-MS intervention is specifically a stretching exercise prescription. All exercise movements are consistent throughout the program. At the beginning of the program, the stretching exercise sessions will take five minutes (1 set) three days per week (15 minutes per week). By the end of the 16-week program, the sessions will take about 30 minutes (2 sets) to be performed three days per week (1.5 hours per week).

Primary Outcomes

  • Change in Depression Severity (self-report) (baseline (week 0), immediate follow-up (week 16 or 4 months), and long-term follow-up (week 32 or 8 months))
  • Change in Depression Severity (observer-rated) (baseline (week 0), immediate follow-up (week 16 or 4 months), and long-term follow-up (week 32 or 8 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-04-01
Completion: 2026-10-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 146 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Illinois at Chicago
Collaborators: Congressionally Directed Medical Research Programs
Principal Investigators:
  • Robert W Motl, PhD (PRINCIPAL_INVESTIGATOR) - University of Illinois at Chicago
Contact Information
Study Contact:
Robert W Motl, PhD
205-975-1306
robmotl@uic.edu
Robert W Motl, PhD
3124137850
robmotl@uic.edu
University of Illinois at Chicago
Interventions
  • Behavioral: POWER-MS — The POWER-MS intervention includes both aerobic exercise and resistance exercise: Aerobic Exercise: The goal of the aerobic exercise training is for participants to achieve three moderate-intensity walking sessions of 30+ minutes per session by the end of the 16-week intervention. Resistance Exercise: Participants will complete resistance exercise training that consists of 1-2 sets (10-15 repetitions) of 5-10 exercises targeting the lower body, upper body, and core muscle groups performed three days per week, with the sets, repetitions and number of exercises increasing based on an individualized difficulty level.
  • Behavioral: FLEX-MS — The FLEX-MS intervention is specifically a stretching exercise prescription. All exercise movements are consistent throughout the program. At the beginning of the program, the stretching exercise sessions will take five minutes (1 set) three days per week (15 minutes per week). By the end of the 16-week program, the sessions will take about 30 minutes (2 sets) to be performed three days per week (1.5 hours per week).
Study Locations (1 sites)
University of Illinois at Chicago, Chicago, Illinois 60612 United States
Eligibility Criteria
Inclusion Criteria * Physical confirmed diagnosis of Multiple Sclerosis (MS) * Diagnosis of Major Depressive Disorder (MDD) - see below (MINI) * English as primary language * Eligible age (between 18 and 64 years old) * Relapse and steroid free in past 30 days * Internet and email access * Willingness to complete the testing and questionnaires, wear the accelerometer, undergo randomization, and engage in exercise testing Exclusion Criteria * Godin Leisure Time Exercise Questionnaire (GLTEQ): Exclude if health contribution score of 14 units or more. This assessment is administered to confirm insufficient baseline physical activity (i.e., not meeting current PA guidelines) * Patient Determined Disease Steps (PDDS): Exclude if score above '2' (i.e., greater than mild ambulatory disability). This assessment is administered as the proposed intervention focuses on walking as main modality for exercise training. The scale asks the participant to describe their walking situation on a scale of 0 to 8; where lower scores indicate better walking ability. * Beck Depression Inventory-Fast Screen (BDI-FS): Exclude if a score less than '4'. The scale measures depression and those with a score of '4' or below likely have very mild depression resulting in floor effects and/or spontaneous remission. * Physical Activity Readiness Questionnaire (PAR-Q): Exclude if more than one yes/affirmative response on this 7-item self-report assessment. This assessment is administered to exclude those individuals who are at a moderate to high risk for contraindications of injury or possible death when undertaking strenuous or maximal exercise. This is a 7-item self-report tool where more than one yes/affirmative response indicates that an individual is not recommended to engage in physical activity within the capacity of this study. Those scoring more than one yes/affirmative response will be further advised to seek medical guidance before becoming more physically active. * Telephone Interview for Cognitive Status (TICS-M): Exclude if scores less than 18. This assessment is administered to ensure that all participants can adequately follow directions. The application of the TICS-M is to ensure that participants do not have severe cognitive impairment that might preclude the ability to adhere to the conditions, understand intervention content, and interact with behavior coaches. * MINI International Neuropsychiatric Interview (version 7.0.2) based on the Diagnostic and Statistical Manual of Mental Disorders V (DSM-V): Include those who meet the criteria for MDD, but exclude for other severe mental illness (obsessive-compulsive disorder, schizophrenia, bipolar or other psychotic disorders) as indicated by the MINI; these persons would require more intensive mental health treatment.
Conditions Persistent Depressive Disorder, Treatmen...
Phase NA
Enrollment 396
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to compare the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) conducted over 16 weeks (acute and continuation treatment) with Behavioral Activation (BA; same dose and duration) in persistently depressed treatment-resistant inpatients regarding efficacy, moderators and mediators of change.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: inpatient CBASP individual therapy — During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 individual CBASP therapy sessions (duration: 50 min per session).
  • Behavioral: inpatient CBASP group therapy — During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 CBASP group therapy sessions (duration: 100 min per session).
  • Behavioral: inpatient CBASP nurse contact — During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 CBASP nurse contact (duration: 25 min per session).
  • Behavioral: inpatient CBASP exercise therapy — During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 CBASP exercise therapy (duration: 75 min per session).
  • Behavioral: outpatient CBASP group therapy — During the 6-week outpatient treatment all patients in this arm will receive 1 CBASP group therapy session (duration: 100 min per session).
  • Behavioral: inpatient BA individual therapy — During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 individual BA therapy sessions (duration: 50 min per session).
  • Behavioral: inpatient BA group therapy — During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 BA group therapy sessions (duration: 100 min per session).
  • Behavioral: inpatient BA nurse contact — During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 BA nurse contact (duration: 25 min per session)

Primary Outcomes

  • Hamilton Depression Rating Scale (HDRS-24), 24-item version (16 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-12-01
Completion: 2028-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 396 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Greifswald
Collaborators: German Research Foundation, University of Kassel, University Medicine Greifswald, Charite University, Berlin, Germany, Hannover Medical School, University Hospital Lübeck, Philipps University Marburg, Ludwig-Maximilians - University of Munich, University Hospital Tuebingen, University Hospital, Bonn, Jena University Hospital
Principal Investigators:
  • Eva-Lotta Brakemeier, Prof. Dr. (PRINCIPAL_INVESTIGATOR) - University Greifswald
Contact Information
Study Contact:
Eva-Lotta Brakemeier, Prof. Dr.
+49 3834 420
eva-lotta.brakemeier@uni-greifswald.de
Johannes Zimmermann, Prof. Dr.
+49 561 804
jz@uni-kassel.de
Stephan Köhler, Prof. Dr.
49-30-450
stephan.koehler@charite.de
Charité, University Medicine Berlin
Interventions
  • Behavioral: inpatient CBASP individual therapy — During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 individual CBASP therapy sessions (duration: 50 min per session).
  • Behavioral: inpatient CBASP group therapy — During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 CBASP group therapy sessions (duration: 100 min per session).
  • Behavioral: inpatient CBASP nurse contact — During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 CBASP nurse contact (duration: 25 min per session).
  • Behavioral: inpatient CBASP exercise therapy — During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 CBASP exercise therapy (duration: 75 min per session).
  • Behavioral: outpatient CBASP group therapy — During the 6-week outpatient treatment all patients in this arm will receive 1 CBASP group therapy session (duration: 100 min per session).
Study Locations (8 sites)
Charité, University Medicine Berlin, Berlin, State of Berlin 10117 Germany
Universitätsklinikum Bonn, Bonn, 53127 Germany
Medizinische Hochschule Hannover, Hanover, 30625 Germany
Universitätsklinikum Jena, Jena, 07743 Germany
Universität zu Lübeck, Lübeck, 23562 Germany
Universitätsklinikum Marburg, Marburg, 35039 Germany
Klinikum der Universität München, München, 80336 Germany
Universitätsklinikum Tübingen, Tübingen, 72076 Germany
Eligibility Criteria
Inclusion Criteria: * Primary DSM-5 diagnosis of PDD (300.4, 296.2x, 296.3x) * Total Hamilton Depression Rating Scale (HDRS-24) Score ≥ 20 * Treatment-resistance (TR) (defined by the ATHF-SF or medication intolerance or one psychotherapy at least 25 sessions by a certified therapist in the current episode) * Sufficient knowledge of the German language * Written informed consent Exclusion Criteria: * Bipolar I or II disorder * Active substance use disorders (abstinence shorter than 6 months) * Schizophrenia spectrum and other psychotic disorders * Antisocial personality disorder * Acute suicidality (HRSD item 3 \> 2 or agreement with C-SSRS item 4 and/or item 5) * Previous CBASP or BA treatment within the last year * Inability to tolerate CBASP or BA (e.g., organic brain disorders, severe cognitive deficits) * Inability to participate in dayclinic or outpatient continuation treatment * Participation in another (psycho)therapeutic study of an interventional nature
Conditions Pregnancy, Postpartum, Childbirth, Healt...
Phase NA
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Regular exercise during pregnancy and postpartum leads to health benefits for mother and child. Inactivity during pregnancy and after delivery is now treated as risky behavior. Physically active pregnant women significantly less often suffer from, among others, gestational diabetes, excessive weight gain, lipids disorders, hypertension, preeclampsia, depressive symptoms, functional and structural disorders, including stress urinary incontinence, back pain or diastasis recti abdominis (DRA). Prenatal physical activity reduces the risk of premature delivery and miscarriage, fetal macrosomia, complications in labor or the risk of metabolic disorders in children. High-intensity interval training (HIIT) has become one of the most popular trends in the fitness sector. The effectiveness of HIIT on a number of health indicators has been proven in various populations but limited data are available on HIIT during pregnancy. The first hypothesis is that the HIIT, implemented during pregnancy and after childbirth, as a stronger exercise stimulus, will have a better impact on selected biological and psychological parameters of mothers, as well as on selected health parameters of their children, compared to the MICT (moderate intensity continuous training). Therefore, it promises better preventive effects on pregnancy complications and ailments as well as non-communicable diseases occurring in these populations. In the second hypothesis, it was assumed that HIIT and MICT implemented during pregnancy and after childbirth, tailored to the specific needs of the perinatal period, will not differ in the effectiveness of maintaining normal functional parameters in women, including prevention of urinary incontinence, back pain, DRA, etc. Pregnant women who apply for the study will be divided into three groups: those attending the HIIT, MICT or educational programs. During the study, the participants will be under standard obstetric care. As comparative groups, non-pregnant women will be also recruited. The investigators will collect data on selected biological, functional and psychological parameters in the study women at each trimester of pregnancy, during the puerperium and one year after childbirth. The data from the medical documentation on the course of childbirth and the assessment of the new-born, as well as the results of preventive examinations in the study women's children aged one, two, four and six years will be also analyzed.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Behavioral: High intensity interval training program for pregnant women — Pregnant women will participate in 8-week HIIT cycles until the day of delivery, 3 times a week, in a volume of each session of 60 minutes. The main part (15-20 min) will be conducted in a form of high intensity intervals, approx. 85-90% of maximum exercise capacity. The intervals will consist of performing exercises for 30-60 seconds, alternating with a 30-60 second rest break, in the ratio of exercise time to rest 1:2, 1:1 or 2:1, according to the individual possibilities of the participant and taking into account the training progression and stage of pregnancy. The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test. After birth, women will participate in 3-month HIIT cycles from the moment of achieving postpartum readiness to training until one year postpartum. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman.
  • Behavioral: Moderate intensity continuous training program for pregnant women — Pregnant women will participate in 8-week MICT cycles until the day of delivery, 3 times a week, in a volume of each session of 60 minutes. The main part (20-25 min) will be conducted in a form of moderate intensity continuous exercise, of 70-80% of the maximum exercise capacity, e.g. in the form of high- and low-impact aerobics choreography with music. The sessions will also include resistance, neuromotor, body posture and flexibility exercises (25 min), breathing exercises, relaxation and visualization of pregnancy or childbirth (10 min). The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test. After birth, women will participate in 3-month MICT cycles from the moment of achieving postpartum readiness to training until one year postpartum. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman.
  • Behavioral: Standard obstetric care with extended education on healthy lifestyle — Pregnant women will get standard obstetric care according to the national law. They will attend educational sessions on a healthy lifestyle, physical activity in the perinatal period and selected aspects of pregnancy and motherhood. Educational classes will be conducted online in real time, at least once every two weeks, until one year postpartum.
  • Behavioral: High intensity interval training program for nonpregnant women — Nonpregnant women will participate in 8-week HIIT cycles for a period of 8 months, 3 times a week, in a volume of each session of 60 minutes. The main part (15-20 min) will be conducted in a form of high intensity intervals, approx. 85-90% of maximum exercise capacity. The intervals will consist of performing exercises for 30-60 seconds, alternating with a 30-60 second rest break, in the ratio of exercise time to rest 1:2, 1:1 or 2:1, according to the individual possibilities of the participant and taking into account the training progression. The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test. For the next 12 months of the project, women will participate in 3-month HIIT cycles. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman.
  • Behavioral: Moderate intensity continuous training program for nonpregnant women — Nonpregnant women will participate in 8-week MICT cycles for a period of 8 months, 3 times a week, in a volume of each session of 60 minutes. The main part (20-25 min) will be conducted in a form of moderate continuous intensity exercise, of 70-80% of the maximum exercise capacity, e.g. in the form of high- and low-impact aerobics choreography with music. The sessions will also include resistance, neuromotor, body posture and flexibility exercises (25 min), breathing exercises and relaxation (10 min). The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test. For the next 12 months of the project, women will participate in 3-month MICT cycles. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman.
  • Behavioral: Standard health care with extended education on healthy lifestyle — Nonpregnant women will get standard health care according to the national law. They will attend educational sessions on a healthy lifestyle, physical activity and selected aspects of preparation to pregnancy and motherhood. Classes will be conducted online in real time, at least once every two weeks, for a period of 20 months.

Primary Outcomes

  • Changes in maternal oxygen consumption, during and after pregnancy (Before starting the intervention and after the completion of each training or educational cycle (during the first 8 months or until birth each training or education cycle lasts 8 weeks; during the next 12 months each cycle lasts 3 months).)
  • Changes in maternal heart rate, during and after pregnancy (Before starting the intervention and after the completion of each training or educational cycle (during the first 8 months or until birth each training or education cycle lasts 8 weeks; during the next 12 months each cycle lasts 3 months).)
  • Changes in systolic blood pressure, during and after pregnancy (Before starting the intervention and after the completion of each training or educational cycle (during the first 8 months or until birth each training or education cycle lasts 8 weeks; during the next 12 months each cycle lasts 3 months).)
  • Changes in diastolic blood pressure, during and after pregnancy (Before starting the intervention and after the completion of each training or educational cycle (during the first 8 months or until birth each training or education cycle lasts 8 weeks; during the next 12 months each cycle lasts 3 months).)
  • Changes in blood glucose level, during and after pregnancy (Before starting the intervention and after the completion of each training or educational cycle (during the first 8 months or until birth each training or education cycle lasts 8 weeks; during the next 12 months each cycle lasts 3 months).)
  • Changes in triglycerides, during and after pregnancy (Before starting the intervention and after the completion of each training or educational cycle (during the first 8 months or until birth each training or education cycle lasts 8 weeks; during the next 12 months each cycle lasts 3 months).)
  • Changes in high-density lipoproteins, during and after pregnancy (Before starting the intervention and after the completion of each training or educational cycle (during the first 8 months or until birth each training or education cycle lasts 8 weeks; during the next 12 months each cycle lasts 3 months).)
  • Changes in urea, during and after pregnancy (Before starting the intervention and after the completion of each training or educational cycle (during the first 8 months or until birth each training or education cycle lasts 8 weeks; during the next 12 months each cycle lasts 3 months).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-06-24
Completion: 2031-08-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gdansk University of Physical Education and Sport
Collaborators: Medical University of Gdansk, University of Gdansk, Pomeranian Medical University Szczecin
Principal Investigators:
  • Anna N Szumilewicz, Assoc. Prof. (PRINCIPAL_INVESTIGATOR) - Gdansk University of Physical Activity and Sport
Contact Information
Study Contact:
Anna N Szumilewicz, Assoc. Prof.
601880207
anna.szumilewicz@awf.gda.pl
Żaneta Wojdakowska
58 55 47 101
nauka@awf.gda.pl
Anna N Szumilewicz, Assoc. Prof.
601880207
anna.szumilewicz@awf.gda.pl
Laboratory of Physical Effort and Genetics in Sport at Gdansk University of Physical Education and Sport
Interventions
  • Behavioral: High intensity interval training program for pregnant women — Pregnant women will participate in 8-week HIIT cycles until the day of delivery, 3 times a week, in a volume of each session of 60 minutes. The main part (15-20 min) will be conducted in a form of high intensity intervals, approx. 85-90% of maximum exercise capacity. The intervals will consist of performing exercises for 30-60 seconds, alternating with a 30-60 second rest break, in the ratio of exercise time to rest 1:2, 1:1 or 2:1, according to the individual possibilities of the participant and taking into account the training progression and stage of pregnancy. The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test. After birth, women will participate in 3-month HIIT cycles from the moment of achieving postpartum readiness to training until one year postpartum. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman.
  • Behavioral: Moderate intensity continuous training program for pregnant women — Pregnant women will participate in 8-week MICT cycles until the day of delivery, 3 times a week, in a volume of each session of 60 minutes. The main part (20-25 min) will be conducted in a form of moderate intensity continuous exercise, of 70-80% of the maximum exercise capacity, e.g. in the form of high- and low-impact aerobics choreography with music. The sessions will also include resistance, neuromotor, body posture and flexibility exercises (25 min), breathing exercises, relaxation and visualization of pregnancy or childbirth (10 min). The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test. After birth, women will participate in 3-month MICT cycles from the moment of achieving postpartum readiness to training until one year postpartum. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman.
  • Behavioral: Standard obstetric care with extended education on healthy lifestyle — Pregnant women will get standard obstetric care according to the national law. They will attend educational sessions on a healthy lifestyle, physical activity in the perinatal period and selected aspects of pregnancy and motherhood. Educational classes will be conducted online in real time, at least once every two weeks, until one year postpartum.
  • Behavioral: High intensity interval training program for nonpregnant women — Nonpregnant women will participate in 8-week HIIT cycles for a period of 8 months, 3 times a week, in a volume of each session of 60 minutes. The main part (15-20 min) will be conducted in a form of high intensity intervals, approx. 85-90% of maximum exercise capacity. The intervals will consist of performing exercises for 30-60 seconds, alternating with a 30-60 second rest break, in the ratio of exercise time to rest 1:2, 1:1 or 2:1, according to the individual possibilities of the participant and taking into account the training progression. The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test. For the next 12 months of the project, women will participate in 3-month HIIT cycles. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman.
  • Behavioral: Moderate intensity continuous training program for nonpregnant women — Nonpregnant women will participate in 8-week MICT cycles for a period of 8 months, 3 times a week, in a volume of each session of 60 minutes. The main part (20-25 min) will be conducted in a form of moderate continuous intensity exercise, of 70-80% of the maximum exercise capacity, e.g. in the form of high- and low-impact aerobics choreography with music. The sessions will also include resistance, neuromotor, body posture and flexibility exercises (25 min), breathing exercises and relaxation (10 min). The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test. For the next 12 months of the project, women will participate in 3-month MICT cycles. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman.
Study Locations (1 sites)
Laboratory of Physical Effort and Genetics in Sport at Gdansk University of Physical Education and Sport, Gdansk, Pomeranian Voivodeship 80-336 Poland
Eligibility Criteria
Inclusion Criteria: Criteria: Inclusion Criteria: For pregnant women: 1. course of pregnancy allowing participation in physical activities adapted to pregnant women 2. consent of the obstetric care provider to participate in the study tests and exercise classes; 3. taking part in all diagnostic and control tests to assess selected biological, functional and psychological parameters at each trimester of pregnancy, during the puerperium and one year after childbirth; 4. participant's consent to use data from the medical documentation on the course of childbirth and the assessment of the new-born, as well as the results of preventive examinations in children aged one, two, four and six, routinely performed according to the Polish pediatric care system; 5. availability to participate in classes three times a week until the day of delivery; 6. declaration of participation in postpartum classes at least once a week and self-completion of the exercise program according to written instructions prepared by the exercise specialist; 7. women can participate in the exercise programs regardless of their level of fitness or exercise capacity, as well as the level of motor skills (based on the diagnostic exercise tests, the exercise program will be tailored to the individual needs and capabilities of a woman). For nonpregnant women: 1. nulliparous; 2. lack of diagnosed infertility and other disorders of the reproductive system; 3. taking part in all diagnostic and control tests to assess selected biological, functional and psychological parameters at indicated time points: before and after each of the 8-week exercise program during the first 8 months of the study and once every 3 months during the following twelve months of the study 4. declaration of availability to participate in exercise classes three times a week for the first 8 months of the program (attendance at least 80% is required); 5. declaration of participation in classes at least once a week and self-completion of the exercise program to the required 150 minutes of physical activity per week, according to the written guidelines prepared by the instructor, for the next 12 months of the program; 6. women can participate in the exercise program regardless of their level of fitness or exercise capacity, as well as the level of motor skills (based on the diagnostic exercise tests, the exercise program will be tailored to the individual needs and capabilities of a woman). Exclusion Criteria for Pregnant and Nonpregnant Women: 1. contraindications to increased physical effort or to any of the diagnostic or control tests; 2. allergies to materials used during diagnostic and control tests (e.g. nickel present in steel plates of vaginal electrodes, disinfectants); 3. other conditions that, according to the researchers, will threaten the health or safety of the participants or will significantly affect the quality of the collected data.
Conditions Breast Neoplasm Female
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The incidence of breast cancer and its mortality are reduced thanks in particular to early detection. Often performed after a screening test, stereotactic macrobiopsies are used to characterize abnormalities detected on mammography. This anxiety-inducing and painful examination leads to significant physiological and psychological modifications for these women who logically apprehend the realization of this act. Faced with this observation, investigators wondered what could be done to improve the experience of the patients during this examination. Investigators were interested in hypnosis because its effectiveness as a complementary practice has been validated by numerous studies with benefits on pain and stress management. However, today, there are no convincing results confirming which hypnosis method would be the best to manage patients' anxiety and pain during this examination.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Sequential Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Behavioral: Preparation in Self-Hypnosis by anchoring — Preparation in Self-Hypnosis by anchoring just before examination
  • Behavioral: Conversational Hypnosis — Conversational Hypnosis during examination
  • Behavioral: Preparation in Self-Hypnosis by anchoring + Conversational Hypnosis — Preparation in Self-Hypnosis by anchoring just before examination combied with Conversational Hypnosis during examination

Primary Outcomes

  • change in anxiety score (baseline (pre-intervention, during the intervention, immediatly after the intervetion) and at 8 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-10-11
Completion: 2025-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital St. Joseph, Marseille, France
Contact Information
Study Contact:
Vanessa MILIEN
0488731070
vmilien@hopital-saint-joseph.fr
Vanessa MILIEN
Hôpital Saint Joseph
Interventions
  • Behavioral: Preparation in Self-Hypnosis by anchoring — Preparation in Self-Hypnosis by anchoring just before examination
  • Behavioral: Conversational Hypnosis — Conversational Hypnosis during examination
  • Behavioral: Preparation in Self-Hypnosis by anchoring + Conversational Hypnosis — Preparation in Self-Hypnosis by anchoring just before examination combied with Conversational Hypnosis during examination
Study Locations (1 sites)
Hôpital Saint Joseph, Marseille, France
Eligibility Criteria
Inclusion Criteria: * aged 18 or over, * referred to the medical imaging department of Saint-Joseph hospital for breast macrobiopsy, * naive of any hypnosis, * having given free, informed and written consent, * being affiliated to a social security scheme or beneficiary of such scheme Exclusion Criteria: * having a major hearing loss, * suffering from identified mental or psychotic disorders, * not understanding the French language, * having already had hypnosis practices, * having an ongoing pregnancy, * being the subject of a safeguard measure
Conditions Premenopausal HR+/HER2- Metastatic Breas...
Phase PHASE2
Enrollment 178
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a prospective, two-arm, randomized phase II study of talazoparib versus talazoparib plus atezolizumab in ER+ premeonopausal women with metastatic breast cancer harboring HRD scar 1st line treatment: GnRH agonist + Aromatase Inhibitor(AI) + Palbociclib 28 days after the last treatment of 1st line treatment(., randomization for 2nd line treatment is conducte to arm A(Talazoparib+Atezolizumab) and arm B(Talazoparib monotherapy)

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, Atezolizumab — * Palbociclib 125mg * AI * GnRH agonist (or ET + CDK4/6 inhibitors + GnRH agonist) * Talazoparib * Atezolizumab
  • Drug: Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, — * Palbociclib 125mg * AI * GnRH agonist (or ET + CDK4/6 inhibitors + GnRH agonist) * Talazoparib

Primary Outcomes

  • 2nd Progression free survival (PFS) (The time until the time of the first event(the progression of a recorded disease of breast cancer or death from all causes) in 2nd line treatment. Up to 72months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-08-25
Completion: 2027-12-31
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 178 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Samsung Medical Center
Contact Information
Study Contact:
Yeon Hee Park, phD
+82-2-3410-1780
yeonh.park@samsung.com
mieun Kim, CRA
+82 2-2148-7664
mieun2728.kim@samsung.com
Yeon Hee Park, phD
82-2-3410-1780
yeonh.park@samsung.com
Samsung medical Center
Interventions
  • Drug: Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, Atezolizumab — * Palbociclib 125mg * AI * GnRH agonist (or ET + CDK4/6 inhibitors + GnRH agonist) * Talazoparib * Atezolizumab
  • Drug: Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, — * Palbociclib 125mg * AI * GnRH agonist (or ET + CDK4/6 inhibitors + GnRH agonist) * Talazoparib
Study Locations (1 sites)
Samsung medical Center, Seoul, Gannam-gu 06351 South Korea
Eligibility Criteria
* Eligibility criteria prior to 1L treatment: 1. Histologically confirmed metastatic breast cancer with or without measurable disease 2. Patients who have stage IV breast cancer at diagnosis (de novo) or have progressed on distant metastatic sites after curative surgery: locally advanced disease not amenable to distant metastasis are eligible as well as disease with distant metastasis 3. Confirmed germline pathogenic BRCA1 and/or 2 mutation or 35 HRD-related gene alterations (see Appendix 16.5) 4. age \> 19 years 5. ECOG performance status 0 - 2 6. Patient has HER2 IHC0, IHC1+, or ICH2+/ISH-, as determined according to ASCO/CAP guidelines breast cancer 7. Patient has ER positive and/or PgR positive according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, defined as 1% of tumor cells stained positive based on the most recent tumor biopsy and assessed locally 8. Female patients should be premenopausal. Premenopausal status is defined as either: A. Patient had last menstrual period within the last 12 months B. If on tamoxifen within the past 3 months, with a plasma estradiol ≥10 pg/mL and FSH ≤40 IU/l or in the premenopausal range, according to local laboratory definition C. in case of chemotherapy induced amenorrhea, with a plasma estradiol ≥10 pg/mL) and/or FSH ≤40IU/l or in the premenopausal range according to local laboratory definition. 9. Patient with treatment history as bellows: A. In patients with de novo metastatic breast cancer(who had stage IV disease at first diagnosis of breast cancer), B. In patients with recurrent metastatic breast cancer, recurrence during or after completion or discontinuation of adjuvant endocrine therapy (regardless of the treatment free interval) are eligible. C. One line of prior cytotoxic chemotherapy(except platinum based chemotherapy) in metastatic breast cancer is permitted. 10. No possibility of pregnancy and/or urine or serum beta-HCG negative 11. Adequate bone marrow function (≥ ANC 1,500/ul, ≥ platelet 100,000/ul, ≥ Hemoglobin 9.0 g/dl) 12. Adequate renal function (≤ serum creatinine 1.5 mg/dl or CCr ≥ 60 ml/min) 13. Adequate liver function (≤ serum bilirubin 2.0 mg/dl, ≤ AST/ALT x 3 upper normal limit). If the subject has liver metastasis, AST/ALT x 5 upper normal limit is acceptable. 14. Patients who were already established on bisphosphonate therapy or denosumab may continue. 15. Patients agreed to use effective contraception or not of childbearing potential 16. Written informed consent 17. Patients agreed to offer tumor tissue and blood for biomarker analysis * Exclusion criteria prior to 1L treatment 1. Postmenopausal women except women who had BSO (Bilateral Salpingo Oophorectomy) 2. Serious uncontrolled intercurrent infections within 4 weeks prior to Cycle 1 Day 1 of 1st Treatment 3. Serious intercurrent medical or psychiatric illness, including active cardiac disease 4. Participants who are pregnant or breast feeding or intending to become pregnant during the study or within 5 months after the final dose of study treatments. 5. Second primary malignancy(except in situ carcinoma of the cervix or adequately treated nonmelanomatous carcinoma of the skin or favorable thyroid papillary carcinoma(follicular thyroid cancer, including PTC) or other malignancy treated at least 5 years previously with no evidence of recurrence) 6. Patients has received previous endocrine treatments in the metastatic setting (Except tamoxifen only ± GnRH agonist) 7. Patients has received previous aromatase inhibitor (less than 1 year after the last dose) 8. Patients has received previous treatment with CDK 4/6 inhibitors, OR PARP1 inhibitors, OR immune check point inhibitors (less than 1 year after the last dose) 9. Known brain metastases, symptomatic or asymptomatic 10. History of clinically significant liver disease, current alcohol abuse or known active infection 11. History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus (SLE), rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis 12. Prior allogeneic stem cell or solid organ transplantation 13. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e. bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest computerised tomography (CT) scan 14. Active tuberculosis 15. Receipt of a live, attenuated vaccine within 4 weeks prior to Cycle 1 Day 1 of 1st Treatment or anticipation that a live, attenuated vaccine will be required during atezolizumab treatment or within 5 months after the last dose of atezolizumab 16. Treatment with systemic immunostimulatory agents (including but not limited to interferons or interlukin \[IL\]-2) within 4 weeks or five half-lives of the drug (whichever is longer) prior to Cycle 1 Day 1 of 1st Treatment 17. Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, mycophenolate, and anti-tumour necrosis factor \[TNF\] agents) within 2 weeks prior to Cycle 1 Day 1 of 1st Treatment, or anticipated requirement for systemic immunosuppressive medications during the trial * Inclusion criteria prior to 2L treatment * For subjects who were enrolled in the 1L treatment part of the study, inclusion criteria 1)-4) should be met. * For subjects who were not enrolled in the 1L treatment part of the study, all of the following inclusion criteria should be met prior to the study enrollment. 1. ECOG performance status 0 - 2 2. Adequate bone marrow function (≥ANC 1,500/ul, ≥platelet 100,000/ul, ≥Hemoglobin 9.0 g/dl) 3. Adequate renal function (≤ serum creatinine 1.5 mg/dl or CCr ≥ 60 ml/min) 4. Adequate liver function (≤ serum bilirubin 2.0 mg/dl, ≤ AST/ALT x 3 upper normal limit) If the subject has liver metastasis, AST/ALT x 5 upper normal limit is acceptable 5. Histologically confirmed metastatic or locally advanced breast cancer that is not amenable to curative surgery, with or without measurable disease. Patients who have stage IV breast cancer at diagnosis (de novo) or have progressed on distant metastatic sites after curative surgery are eligible. 6. Prior treatment with endocrine-based therapy + CDK4/6 inhibitor for metastatic or inoperable locally advanced breast cancer. Allowed endocrine-based therapy is as below: A. Aromatase Inhibitor B. For subjects who had disease progression during or after the adjuvant aromatase inhibitor therapy, fulvestrant C. Up to one line of chemotherapy for metastatic or inoperable locally advanced breast cancer is allowed except for platinum based chemotherapy. 7. Confirmed germline pathogenic BRCA1 and/or BRCA2 mutation or 35 HRD-related gene alterations (see Appendix 16.5) 8. age \> 19 years 9. Patient has HER2 IHC0, IHC1+, or ICH2+/ISH-, as determined according to ASCO/CAP guidelines breast cancer 10. Patient has ER positive and/or PgR positive according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, defined as 1% of tumor cells stained positive based on the most recent tumor biopsy and assessed locally 11. Female patients should be premenopausal. Premenopausal status is defined as either: A. Patient had last menstrual period within the last 12 months B. If on tamoxifen within the past 3 months, with a plasma estradiol ≥10 pg/mL and FSH ≤40 IU/l or in the premenopausal range, according to local laboratory definition C. in case of chemotherapy indu
Conditions Breast Cancer
Phase PHASE2
Enrollment 96
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: HCQ — 600 mg tablets twice daily D1-28 of each 28-day cycle
  • Drug: Avelumab — 10 mg/kg, IV, D1 and D15 of each 28-day cycle
  • Drug: Palbociclib — 125 mg capsule daily, by mouth on D1-21 concurrently with Avelumab. Or 75 mg capsule daily, by mouth on D1-28 concurrently with HCQ.

Primary Outcomes

  • Determine the efficacy of HCQ or Avelumab, alone or in combination with Palbociclib, in eradicating DTCs (Efficacy is assessed at the end of Cycle 6 (each cycle is 28 days).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-06-01
Completion: 2028-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 96 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Abramson Cancer Center at Penn Medicine
Collaborators: Johns Hopkins University, Translational Breast Cancer Research Consortium, Pfizer, Breast Cancer Research Foundation
Principal Investigators:
  • Angela DeMichele, MD (PRINCIPAL_INVESTIGATOR) - University of Pennsylvania
Contact Information
Study Contact:
Lauren Bayne, PhD
215-615-2367
breastcancerclinicaltrials@pennmedicine.upenn.edu
Pauleen Sanchez, BA
215-615-2367
breastcancerclinicaltrials@pennmedicine.upenn.edu
Claudine Isaacs, MD
isaacsc@georgetown.edu
Georgetown University
Interventions
  • Drug: HCQ — 600 mg tablets twice daily D1-28 of each 28-day cycle
  • Drug: Avelumab — 10 mg/kg, IV, D1 and D15 of each 28-day cycle
  • Drug: Palbociclib — 125 mg capsule daily, by mouth on D1-21 concurrently with Avelumab. Or 75 mg capsule daily, by mouth on D1-28 concurrently with HCQ.
Study Locations (7 sites)
Georgetown University, Washington D.C., District of Columbia 20007 United States
University of Chicago, Chicago, Illinois 60637 United States
Indiana University, Indianapolis, Indiana 46202 United States
Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States
Vanderbilt University, Nashville, Tennessee 37232 United States
University of Washington, Seattle, Washington 98195 United States
Eligibility Criteria
Inclusion Criteria: * Bone marrow aspirate after completion of all definitive therapy demonstrates detectable DTCs (via IHC) as performed by central laboratory assessment at University of Pennsylvania. * History of stage II-III histologically-confirmed ER+/Her2 neg invasive breast cancer with no evidence of recurrent local or distant disease (by American Joint Committee on Cancer 7th edition). Patients with bilateral breast cancer are eligible, so long as both cancers are ER+/Her2 neg, at least one meets other eligibility criteria and patient is treated with curative intent. For patients who undergo neoadjuvant therapy, eligibility is based upon pathologic stage of residual disease at surgery. * ER+/Her2 neg receptor status on breast primary tumor (by American Society of Clinical Oncology/College of American Pathologists guidelines). Any partial response (PR) status is allowed. Tumors that are ER negative and PR positive are not eligible. Patients who undergo neoadjuvant therapy are eligible if either the pre-treatment biopsy or residual disease at surgery is ER+/Her2 neg. * Patients must have completed all primary and adjuvant therapy (including surgery, chemotherapy, and radiation) with the exception of adjuvant endocrine therapy. Prior treatment-related toxicity must be resolved to ≤ Grade 1 with the exception of alopecia and peripheral neuropathy, prior to study enrollment. * Patients may have received prior CDK4/6 inhibitor therapy with an agent other than Palbociclib. Patients must have discontinued CDK4/6 inhibitor at least 6 months prior to screening. * Patients must be receiving adjuvant endocrine therapy at the time of enrollment. Patients are eligible to enroll within 2-7 years after initiation of adjuvant endocrine therapy. Use of tamoxifen as adjuvant endocrine therapy during study treatment is not allowed on hydroxychloroquine arms due to the potential drug-drug interaction with hydroxychloroquine. However, patients on tamoxifen at the time of screening may enroll on the treatment trial if switched to an aromatase inhibitor at least 21 days prior to starting study therapy in the event patient is randomized to a hydroxychloroquine containing arm. Premenopausal patients on concurrent ovarian suppression are eligible. Patients on any other adjuvant endocrine therapy, including any investigational therapy, are ineligible. * Patients receiving bone modifying agents (bisphosphonates or rank-ligand inhibitors) at the time of screening may continue this therapy. Bone modifying agents may not be initiated while receiving study treatment. * No concurrent enrollment on another investigational therapy clinical trial. * Men and women, age ≥ 18 years. * No contraindications to the study medications (refer to Section 7.2) or uncontrolled medical illness. * Adequate bone marrow, liver, and renal function and other parameters. * Ability to speak and understand English Exclusion Criteria: * Patients with a history of another prior invasive breast cancer are ineligible. Patients with prior Ductal carcinoma in situ (DCIS) of the breast are eligible if this was diagnosed \> 5 years prior to enrollment. Patients with prior invasive malignancy other than breast cancer are eligible if they have been disease-free for at least 5 years prior to enrollment. * Patients receiving chronic, high dose systemic treatment with corticosteroids defined as: chronic use of cortisone \>50mg; hydrocortisone \>40mg, prednisone \>10mg, methylprednisone \>8mg or dexamethasone \>1.5mg; or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed. * EKG demonstrating QT interval corrected (QTC) \> 480 ms * Any severe and/or uncontrolled medical conditions or other conditions that could affect subject participation in the study including: * Chronic autoimmune disease * History or evidence of increased cardiovascular risk including any of the following: * Current clinical significant uncontrolled arrhythmias. Exception: Subjects with controlled atrial fibrillation * History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to enrollment * Current ≥ Class II congestive heart failure as defined by New York Heart Association * History of pneumonitis/interstitial lung disease or severely impaired lung function with a previously documented spirometry and Diffusing Capacity of Lung for Carbon Monoxide (DLCO) that is 50% of the normal predicted value (these tests not required at screening; prior results, if performed for standard of care should be referenced) and/or O2 saturation that is 88% or less at rest on room air * Uncontrolled diabetes * Active (acute or chronic) or uncontrolled severe infections * Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis * HIV positive patient who are receiving combination anti-retroviral therapy are ineligible because of the potential for pharmacokinetic interactions or increased immunosuppression with Palbociclib. However, HIV per se is not a contraindication to study participation and HIV testing is not required. * Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of hydroxychloroquine (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection) * Patients with an active, bleeding diathesis. Patients receiving therapeutic anticoagulation are not eligible for study participation. * History of retinopathy or retinal vein occlusion * Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods.
Conditions Mammographic Breast Density, Mammography
Phase NA
Enrollment 210
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate how well women may adopt a Contrast-enhanced Spectral Mammography (CESM) as their yearly breast screening test compared to the standard 2-D or 3-D mammogram.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Device: Contrast-enhanced spectral mammography (CESM) — CESM is a mammogram performed after the injection of IV contrast. CESM is used most often when additional information is needed after a standard mammogram. CESM has also been used to determine the extent of a known breast cancer, to screen patients at high risk for developing breast cancer due to a family history or positive cancer genes, and for women with dense breast tissue. Two images are taken almost at the same time during the exam, after the iodine based contrast injection is administered. The first image is comparable to a regular mammogram. The second image shows areas that take up the contrast (enhance) showing increased blood flow. Breast cancers often enhance with contrast due to a greater amount of blood vessels. Non-cancerous lesions can also have greater blood flow.

Primary Outcomes

  • Evaluate the patient experience during a screening CESM (16 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-09-19
Completion: 2023-06
Eligibility
Age: 40 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 210 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Virginia
Contact Information
Study Contact:
Kathy L Repich, RN
4342434540
klr3b@virginia.edu
Matthew M Miller, MD
MM5CA@hscmail.mcc.virginia.edu
Kathy Repich
434-825-3112
klr3b@virginia.edu
UVA Breast Care Center
Interventions
  • Device: Contrast-enhanced spectral mammography (CESM) — CESM is a mammogram performed after the injection of IV contrast. CESM is used most often when additional information is needed after a standard mammogram. CESM has also been used to determine the extent of a known breast cancer, to screen patients at high risk for developing breast cancer due to a family history or positive cancer genes, and for women with dense breast tissue. Two images are taken almost at the same time during the exam, after the iodine based contrast injection is administered. The first image is comparable to a regular mammogram. The second image shows areas that take up the contrast (enhance) showing increased blood flow. Breast cancers often enhance with contrast due to a greater amount of blood vessels. Non-cancerous lesions can also have greater blood flow.
Study Locations (1 sites)
UVA Breast Care Center, Charlottesville, Virginia 22911 United States
Eligibility Criteria
Inclusion Criteria: * • Female * 40 to 69 years * Previous normal mammogram (BI-RADS 1 or 2) showing heterogeneous or extremely dense breast tissue within last 24 months * Scheduled for screening mammogram as part of the patient's clinical care Exclusion Criteria: * • No mammogram within last 24 months * Fatty or scattered fibroglandular tissue on last mammogram * History of allergy to iodinated contrast * History of renal disease or renal function abnormalities * Pregnant women * History of diabetes * History of paraproteinemia syndromes such as multiple myeloma * History of collagen vascular disease * History of vascular disease (coronary artery disease, myocardial infarction, carotid disease, peripheral vascular disease, or known visceral artery disease) * Previously identified as high risk for breast cancer (\>20% lifetime risk) * Asthma * Sickle Cell Anemia * Currently on Dialysis